Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacokinetics of S-1 and CYP2A6 genotype in Japanese patients with advanced cancer.

Oncology reports - 1 Aug 2010

Hirose Takashi, Fujita Ken-Ichi, Nishimura Kazuko, Ishida Hiroo, Yamashita Keishi, Sunakawa Yu, Mizuno Keiko, Miwa Keisuke, Nagashima Fumio, Tanigawara Yusuke, Adachi Mitsuru, Sasaki Yasutsuna

Abstract excerpt

We developed a population pharmacokinetic (PPK) model of S-1 including the cytochrome P450 (CYP) 2A6 genotype and then used this PPK model to assess the influence of the CYP2A6 genotype on PK parameters of S-1 and the relationship between toxicity and the individual maximum concentrations (Cmax)...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Administration, Oral
Share to Antimetabolites, Antineoplastic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Area Under Curve

Share to Aryl Hydrocarbon Hydroxylases

Share to Cytochrome P-450 CYP2A6

Share to Drug Combinations

Share to Fluorouracil

Share to Metabolic Clearance Rate

Source

Identifiers

PMID: 20596643
DOI: 10.3892/or_00000889

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-20596643-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacokinetics of S-1 and CYP2A6 genotype in Japanese patients with advanced cancer.PMID 20596643Read ↗

CYP2A6 and the plasma level of 5-chloro-2, 4-dihydroxypyridine are determinants of the pharmacokinetic variability of tegafur and 5-fluorouracil, respectively, in Japanese patients with cancer given S-1.Semantic proximity Read ↗

The CYP2A6*4 allele is determinant of S-1 pharmacokinetics in Japanese patients with non-small-cell lung cancer.Semantic proximity Read ↗

Characteristic CYP2A6 genetic polymorphisms detected by TA cloning-based sequencing in Chinese digestive system cancer patients with S-1 based chemotherapy.Semantic proximity Read ↗

Associations between CYP2A6 polymorphisms and outcomes of adjuvant S-1 chemotherapy in patients with curatively resected gastric cancer.Semantic proximity Read ↗

A novel mutant allele of the CYP2A6 gene (CYP2A6*11 ) found in a cancer patient who showed poor metabolic phenotype towards tegafur.Semantic proximity Read ↗

Application of PBPK Modeling and Virtual Clinical Study Approaches to Predict the Outcomes of CYP2D6 Genotype-Guided Dosing of Tamoxifen.Semantic proximity Read ↗

Pharmacogenetic impact of polymorphisms in the coding region of the UGT1A1 gene on SN-38 glucuronidation in Japanese patients with cancer.Semantic proximity Read ↗

The effect of ABCG2 genotype on the population pharmacokinetics of sunitinib in patients with renal cell carcinoma.Semantic proximity Read ↗

Comparison of the pharmacokinetics and pharmacodynamics of S-1 between Caucasian and East Asian patients.Semantic proximity Read ↗

Population pharmacokinetics of gemcitabine and its metabolite in Japanese cancer patients: impact of genetic polymorphisms.Semantic proximity Read ↗

Population pharmacokinetics and pharmacogenetics of apatinib in adult cancer patients.Semantic proximity Read ↗

Relationship Among Gefitinib Exposure, Polymorphisms of Its Metabolizing Enzymes and Transporters, and Side Effects in Japanese Patients With Non-Small-Cell Lung Cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.